Ignite Creation Date:
2025-12-24 @ 4:19 PM
Ignite Modification Date:
2026-03-03 @ 12:44 AM
Study NCT ID:
NCT02885766
Status:
UNKNOWN
Last Update Posted:
2020-02-17
First Post:
2016-08-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Sponsor:
Fusion Pharma LLC
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CML | View |
| None | Myeloid leukaemia chronic | View |
| None | CML progression | View |
| None | Chronic phase chronic myeloid leukemia | View |
| None | PF-114 | View |
| None | Cytogenetic response CCyR | View |
| None | Major molecular response MMR | View |
| None | Complete molecular response CMR | View |
| None | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | View |
| None | 2-nd generation Bcr-Abl inhibitors resistant | View |